Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021
27 abstracts showcase the Company’s innovation in the areas of immuno-oncology, oncogenic pathways, and DNA damage response (DDR) — in gastrointestinal, genitourinary, and thoracic tumors...